Generic Victoza Availability
Last updated on Jan 11, 2023.
Victoza is a brand name of liraglutide, approved by the FDA in the following formulation(s):
VICTOZA (liraglutide recombinant - solution;subcutaneous)
-
Manufacturer: NOVO NORDISK INC
Approval date: January 25, 2010
Strength(s): 18MG/3ML (6MG/ML) [RLD]
Has a generic version of Victoza been approved?
No. There is currently no therapeutically equivalent version of Victoza available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Victoza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Derivatives of GLP-1 analogs
Patent 6,268,343
Issued: July 31, 2001
Inventor(s): Knudsen; Liselotte Bjerre & Huusfeldt; Per Olaf & Nielsen; Per Franklin & Kaarsholm; Niels C. & Olsen; Helle Birk & Bj.o slashed.rn; S.o slashed.ren Erik & Pedersen; Freddy Zimmerdahl & Madsen; Kjeld
Assignee(s): Novo Nordisk A/SThe present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action.
Patent expiration dates:
- August 22, 2022✓✓✓
- February 22, 2023✓
- August 22, 2022
-
Needle mounting system and a method for mounting a needle assembly
Patent 7,762,994
Issued: July 27, 2010
Inventor(s): Klint; Henrik Sonderskov & Radmer; Jim & Smedegaard; Jorgen K & Nielsen; Jan Frank & Jensen; Peter Moller & Jensen; Jens Moller
Assignee(s): Novo Nordisk A/SA needle mounting system and methods for mounting a needle assembly on a needle mount are disclosed. The needle mounting system includes a needle hub having protrusions extending radially inward. A needle mount has a plurality of slots to receive the protrusions. The slots have a first portion that defines a passageway substantially parallel to a longitudinal axis of the needle mount and a second portion substantially perpendicular to the axis. The needle hub and mount provide a method wherein a needle assembly may be mounted on an injection device without completely rotating the needle hub relative to the needle mount.
Patent expiration dates:
- May 23, 2024✓
- November 23, 2024✓
- May 23, 2024
-
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Patent 8,114,833
Issued: February 14, 2012
Inventor(s): Pedersen; Tina Bjeldskov & Bonde; Claude & Engelund; Dorthe Kot
Assignee(s): Novo Nordisk A/SThe present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation.
Patent expiration dates:
- August 13, 2025✓✓
- February 13, 2026✓
- August 13, 2025
-
Needle mounting system and a method for mounting a needle assembly
Patent 8,579,869
Issued: November 12, 2013
Assignee(s): Novo Nordisk A/SA needle mounting system and methods for mounting a needle assembly on a needle mount are disclosed. The needle mounting system includes a needle hub having protrusions extending radially inward. A needle mount has a plurality of slots to receive the protrusions. The slots have a first portion that defines a passageway substantially parallel to a longitudinal axis of the needle mount and a second portion substantially perpendicular to the axis. The needle hub and mount provide a method wherein a needle assembly may be mounted on an injection device without completely rotating the needle hub relative to the needle mount.
Patent expiration dates:
- June 30, 2023✓
- December 30, 2023✓
- June 30, 2023
-
Stable formulation of modified GLP-1
Patent 8,846,618
Issued: September 30, 2014
Assignee(s): Novo Nordisk A/SPharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.
Patent expiration dates:
- June 27, 2022✓
- December 27, 2022✓
- June 27, 2022
-
Injection button
Patent 9,265,893
Issued: February 23, 2016
Assignee(s): Novo Nordisk A/SA push button connection for an injection device comprising a push button (10) and a driving part (20). The two parts of the push button connection are mounted to each other and is relatively rotatable to each other. In order to minimize the friction occurring between the push button and the driving part when relatively rotated forces are transmitted via a pivot bearing (18, 22). In order also to minimize the effect of forces appearing dislocated from the center line a number of radial bearings (13, 23; 14, 25) having a little friction diameter is provided.
Patent expiration dates:
- September 23, 2032✓
- March 23, 2033✓
- September 23, 2032
-
Liraglutide in cardiovascular conditions
Patent 9,968,659
Issued: May 15, 2018
Assignee(s): Novo Nordisk A/SThe present invention relates to the GLP-1 receptor agonist liraglutide for use in medicine.
Patent expiration dates:
- January 9, 2037✓
- July 9, 2037✓
- January 9, 2037
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- June 17, 2022 - NEW PATIENT POPULATION
- December 17, 2022 - PEDIATRIC EXCLUSIVITY
More about Victoza (liraglutide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (752)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: incretin mimetics
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.